Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. May 15, 2025; 17(5): 104686
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.104686
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.104686
Figure 6 SPDL1 inhibits the malignant biological behaviour of HCT116 cells.
A: Cell counting kit-8 assay; B and C: Transwell migration assay (magnification, 100 ×). The data are presented as the mean ± SD from three independent experiments. aP < 0.05. 1P vs negative control group. 2P vs negative control + U0126 group. Con: Control; NC: Negative control; si-SPDL1: Small interfering RNA targeting SPDL1; OD: Optical density.
- Citation: Peng P, Sun J, Li MS, Cheng RX, Liu SQ, Qin MB, Zhang JX, Huang JA. SPDL1 inhibition enhances colorectal cancer progression via epidermal growth factor receptor/extracellular signal-regulated kinase pathways. World J Gastrointest Oncol 2025; 17(5): 104686
- URL: https://www.wjgnet.com/1948-5204/full/v17/i5/104686.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i5.104686